Starting October 1, 2015, the FDA tropical disease priority review user fee rate is set to increase to $2,727,000, up nearly $200,000 from 2015’s rate of $2,562,000. Under the Prescription Drug User Fee Act (PDUFA) a priority review is intended to get drugs for qualifying tropical diseases (dengue, malaria, cholera, and Ebola) to market faster. FDA intends to review these products within six months of filing (compared to the standard ten months), and was granted the authority to determine and collect fees for these applications under the Food and Drug Administration Amendments Act of 2007. Sponsors wishing to use the priority review voucher must pay the FDA priority review user fee in addition to any other fees required.
The tropical disease priority review user fee rate is assessed and determined on an annual basis, and is “based on the difference between the average cost incurred by FDA in the review of a human drug application subject to priority review in the previous fiscal year, and the average cost incurred by FDA in the review of a human drug application that is not subject to priority review in the previous fiscal year.” According to the Agency, the fee is used to cover the “incremental costs for FDA to do a priority review on a product that would otherwise get a standard review,” and allows it to have the necessary resources that are required to conduct a priority review.
September 30, 2015
FDA has released the fiscal year 2016 fee rate for using a rare pediatric disease priority review voucher. The new rate for 2016 will be $2,727,000, up from 2015’s rate of $2,562,000, and will take...
March 24, 2018
On Friday, March 16th, the FDA published a notice in the Federal Register, stating that the effective date for the amendments related to intended use would be delayed indefinitely. In the notice, the...
August 10, 2016
On Monday, August 8th, the FDA issued a final rule outlining its refuse to accept policy for tobacco product submissions that do not meet the minimum threshold for acceptability for FDA review....